Evidence map›Paper›PMID 34435185›Full record

ReviewMatrix biology plus2021

BMP antagonists in tissue development and disease.

Annkatrin Correns, Laura-Marie A Zimmermann, Clair Baldock, Gerhard Sengle

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Matrix biology plus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Annkatrin CorrensDepartment of Paediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
Laura-Marie A ZimmermannDepartment of Paediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
Clair BaldockWellcome Trust Centre for Cell-Matrix Research, University of Manchester, B.3016 Michael Smith Building, Oxford Road, M13 9PT, Manchester, United Kingdom.
Gerhard SengleDepartment of Paediatrics and Adolescent Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.
University of Cologne · DEUniversity Hospital Cologne · DEWellcome Centre for Cell-Matrix Research · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bone morphogenic proteins (BMPs) are important growth regulators in embryogenesis and postnatal homeostasis. Their tight regulation is crucial for successful embryonic development as well as tissue homeostasis in the adult organism. BMP inhibition by natural extracellular biologic antagonists represents the most intensively studied mechanistic concept of BMP growth factor regulation. It was shown to be critical for numerous developmental programs, including germ layer specification and spatiotemporal gradients required for the establishment of the dorsal-ventral axis and organ formation. The importance of BMP antagonists for extracellular matrix homeostasis is illustrated by the numerous human connective tissue disorders caused by their mutational inactivation. Here, we will focus on the known functional interactions targeting BMP antagonists to the ECM and discuss how these interactions influence BMP antagonist activity. Moreover, we will provide an overview about the current concepts and investigated molecular mechanisms modulating BMP inhibitor function in the context of development and disease.

Indexed as

ActR, activin receptorALK3, anaplastic lymphoma kinase 3ATF2, activating transcription factor 2BDB2, brachydactyly type B2BISC, BMP-induced signalling complexBMP antagonistsBMPER, BMP binding endothelial regulatorBMPs, bone morphogenetic proteinsBone morphogenetic protein (BMP)CAN, cerberus and DANCDD, craniodiaphyseal dysplasiaCHRD domain, chordin specific domainConnective tissue disorderCUB domain, for complement C1r/C1s, Uegf, Bmp1 domainCv2, crossveinless-2DAN, differential screening selected gene aberrative in neuroblastomaDpp, decapentaplegicDSD, diaphanospondylodysostosisECM, extracellular matrixERK, extracellular signal-regulated kinasesExtracellular matrix (ECM)FMF, fibrillin microfibrilsHS, heparan sulphateHSPGs, heparan sulphate proteoglycansMAPKs, mitogen-activated protein kinasesMGC1, megalocornea 1PI3K, phosphoinositide 3-kinasePRDC, protein related to DAN and CerberusScw, screwSog, short gastrulationSOST, sclerostinSYNS1, multiple synostoses syndrome 1TCC, tarsal-carpal coalition syndromeTGF-β, transforming growth factor- βTld, tolloidTsg, twisted gastrulationVBCH, Van Buchem diseasevWC, von Willebrand factor type CvWD, von Willebrand factor type DXlr/Tll, xolloid-related metalloprotease

Identifiers

PMID34435185
PMCPMC8377005
OpenAlexW3169250546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.